版本:
中国

BRIEF-European Medicines Agency accepts design of neuroderm's nd0612 phase III indigo efficacy trial

June 6 Neuroderm Ltd

* European medicines agency accepts design of neuroderm’s nd0612 phase iii indigo efficacy trial

* Says received a scientific advice letter from scientific advice working party of european medicines agency

* Neuroderm - guidance in letter allows co to move forward towards submission of regulatory applications for nd0612 in europe by end of 2018

* Says letter accepts main design elements suggested by neuroderm for amended indigo phase iii efficacy trial

* Neuroderm ltd - ema suggested that co's planned clinical and regulatory development program may be adequate to support a benefit-risk evaluation of nd0612 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐